Since IQOS became available in the market, the focus of the research has been on conducting it in real life conditions. We are looking at how the product is used and by whom, in order to do our best to identify and prevent use or uptake by unintended audiences.
We also monitor reports of health effects now that the product is used by millions of adult users. Long-term studies will eventually help us to evaluate the potential disease–specific risk reduction of IQOS. Gathering data to answer this question takes time, but it’s the right choice. So far, all the data we’ve seen points in the right direction.